Compare DexCom, Inc. (DXCM) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TKO Group Holdings Inc — how do they compare? DexCom, Inc. trades at $90.64 (market cap $33.79B), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: DexCom, Inc. is far larger — about 2.4× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TKO | |
|---|---|---|
Market Cap | $33.79B | $14.24B |
Sector | Health | Technology |
52-Week High | $89.53 | $224.96 |
52-Week Low | $54.84 | $176.49 |
Enterprise Value | $33.24B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
TKO trades at $195.14, up 3.02% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. Recent Q2 2026 results showed revenue of $1.55 billion, an 18% YoY increase, though EPS of $1.34 missed expectations. The company raised full-year guidance, reflecting confidence in media rights and live events. Analyst consensus is strongly bullish with an average price target of $228.17, representing 17% upside from current levels.
TKO's growth trajectory is supported by expanding media deals and global events, but high valuation multiples (P/E 68.33) pose risks if execution falters. Key opportunities include continued revenue momentum from UFC and WWE, while risks involve earnings volatility and competitive pressures. The stock remains attractive for growth-oriented investors despite premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
